Algorithme Pharma is pleased to announce the signing of a strategic alliance with the University of Montreal Hospital Research Centre (CRCHUM), allowing for access to an extensive pool of patients and the new 520,000 sq. ft. research complex (CRCHUM) for conducting complex early stage clinical trials.
(Laval, Québec, Canada May 14, 2013) – The Altasciences Group is proud to announce the addition of Vince and Associates Clinical Research to its team providing comprehensive Phase I/IIa clinical drug development capabilities.
Collaborative results recently presented at the 14th Annual Immunogenicity for Biotherapeutics Conference in Baltimore 18-20 March
TORONTO - SQI Diagnostics Inc. (TSX-V: SQD), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics (“SQI”), and Algorithme Pharma (“Algorithme”) today announced that they have completed the multiplexed proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) biosimilar compounds using SQI’s Ig_PLEX™ multiplexing technology.
Montreal, February 14, 2013 – Lab Bio-Medic and Algorithme Pharma are pleased to announce that they have signed a partnership agreement for the delivery of biomedical analysis required as part of clinical research projects conducted on behalf of pharmaceutical and biotech customers of this world leader in the conduct of Phase I / IIa and bioequivalence clinical trials.
Laval, Quebec, January 25, 2013 – Algorithme Pharma and SQI Diagnostics’ (“SQI”) announced that they are using SQI’s Ig_PlexTM multiplexing technology to develop a multiplex proof of concept assay targeted at immunogenicity testing of heparin and heparin-based low molecular weight (LMWT) compounds.